Online inquiry

IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4044MR)

This product GTTS-WQ4044MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL36RN gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_012275.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26525
UniProt ID Q9UBH0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4044MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ297MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ2589MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ8632MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ7441MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ14981MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ4171MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ638MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ13674MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW